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Bioconjugation Approaches to Produce Subunit Vaccines Composed of Protein or Peptide 
Antigens and Covalently Attached Toll-Like Receptor Ligands 
 
Zhenghui Xu and Peter Michael Moyle* 
School of Pharmacy, The University of Queensland, Woolloongabba 4102, QLD, Australia 
 
Abstract 
Traditional vaccines derived from attenuated or inactivated pathogens are effective at 
inducing antibody-based protective immune responses, but tend to be highly reactogenic, 
causing notable adverse effects. Vaccines with superior safety profiles can be produced by 
subunit approaches, utilizing molecularly defined antigens (e.g. proteins and polysaccharides). 
These antigens, however, often elicit poor immunological responses, necessitating the use of 
adjuvants. Immunostimulatory adjuvants have the capacity to activate antigen presenting cells 
directly through specific receptors (e.g. Toll-like receptors (TLRs)), resulting in enhanced 
presentation of antigens as well as secretion of proinflammatory chemokines and cytokines. 
Consequently, innate immune responses are amplified and adaptive immunity is generated. 
Recently, site-specific conjugation of such immunostimulatory adjuvants (e.g. TLR ligands) 
onto defined antigens has shown superior efficacy over unconjugated mixtures, suggesting 
that the development of chemically-characterized immunostimulatory adjuvants and 
optimized approaches for their conjugation with antigens may provide a better opportunity for 
the development of potent, novel vaccines. This review briefly summarizes various TLR 
agonists utilized as immunostimulatory adjuvants and focuses on the development of 
techniques (e.g. recombinant; synthetic, and semisynthetic) for generating adjuvant-antigen 
fusion vaccines incorporating peptide or protein antigens.  
 
INTRODUCTION 
Vaccination is one of the most important measures for the prevention of infectious diseases. 
Immunization with pathogen-derived antigens can elicit protection against infection caused by 
such pathogens through inducing antigen-specific immune responses. Several different 
vaccine approaches have been developed to date. Of these, the subunit vaccine approach, 
where a molecularly characterized component (e.g. a protein or polysaccharide) is used as an 
antigen, tends to exhibit a better safety profile than traditional whole organism vaccine 
approaches.
1
 By incorporating defined pathogen components, subunit vaccines are able to 
generate defined antigen-specific responses. Furthermore, subunit vaccines can be: produced 
with minimal batch-to-batch variation in good accordance with regulatory requirements; 
designed to incorporate unnatural components that cannot be achieved by purification from 
natural sources; freeze dried for the purpose of stability and simplifying storage and 
transportation logistics; and can be used where pathogens are unable to be grown in culture.
2
 
A broad range of strategies have been used to develop subunit vaccines, including 
recombinant or synthesized proteins and peptides, toxoids, polysaccharides and 
polysaccharide-carrier protein conjugates.
2
 
With the development of recombinant DNA technology, it is convenient to produce 
recombinant protein or peptide antigens in a highly-purified form. But, subunit vaccines, 
involving such antigens, are normally poorly immunogenic and cannot elicit potent immune 
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responses to afford protection on their own.
3
 Adjuvants are therefore needed to enhance the 
immune response of such poorly immunogenic vaccine antigens. Adjuvants are substances 
used in combination with a specific antigen, which together produce a more robust immune 
response than the antigen alone.
4
 Currently only a limited number of adjuvants have been 
licensed for human use, including alum salts, oil-in-water emulsions (MF59 and AS03), 
virosomes and AS04 (which consists of alum and monophosphoryl lipid A (MPLA)).
5-8
 
Although alum is the oldest adjuvant, it is still commonly used in licensed vaccines due to its 
good safety record. Aluminum containing adjuvants can induce TH2 humoral and CD4
+
 T cell 
responses, but in general do not stimulate cytotoxic T lymphocyte (CTL) responses.
9
 Thus, 
the use of alum is inappropriate where cytotoxic T lymphocytes are required for vaccine 
success (e.g. therapeutic vaccines against cancers). Hence there is an urgent need to develop 
new adjuvants that can enhance and shape vaccine-induced responses. Immunopotentiating 
adjuvants, represented by MPLA, are under intense investigation since these types of 
adjuvants can activate the innate immune system via pattern recognition receptors (PRR) 
which subsequently lead to an adaptive immune response.
8
 Dendritic cells (DCs), as TLR 
expressing cells, play a critical role in mediating adaptive immunity. Immunopotentiating 
adjuvants, such as TLR agonists, are thought to target DCs directly, thereby directing the 
balance between humoral and cell-mediated immunity associated with acquired immune 
responses.
8
 From this perspective, the potential of TLR agonists as adjuvants for the next 
generation of vaccines should be explored. Meanwhile, it should be emphasized that any 
safety concerns or unacceptable levels of intolerability caused by adjuvant candidates are not 
acceptable. 
Immunopotentiating adjuvants can be simultaneously delivered with antigens to improve 
vaccine efficacy. Codelivery of antigens and TLR agonists to antigen presenting cells (APCs) 
ensures the colocalization of both molecules to the same endosome or phagosome, within the 
same APC, thereby enhancing the antigen presentation and processing efficiency.
3
 A number 
of strategies including covalent conjugation, encapsulation and entrapping antigens in 
lipid-based vesicles have been developed to fulfill the goal of codelivery.
10-13
 Among these 
strategies, conjugation has received a great deal of attention due to the ability to produce 
molecularly defined conjugates in a controlled manner. Numerous (bio)chemical strategies 
have been developed to covalently attach adjuvant molecules onto antigen peptides or 
proteins, most of which can be summarized into three categories: synthetic, recombinant 
fusion proteins, and semisynthetic approaches.
12,14-19
 The selection of one of these approaches 
needs to be rationally chosen based on the properties of the antigen and adjuvant. For example, 
chemical synthesis offers a cost-effective and feasible way to produce short peptides and 
small proteins and offers significant opportunities to engineer in non-natural components, 
while the routine synthesis of large peptides and proteins are less accessible due to synthetic 
difficulties. On the contrary, recombinant approaches are normally selected for the production 
of large protein molecules, but not peptides or small proteins, since peptides tend to be 
degraded during their expression in host cells.
20
 Further, it is important for many protein 
antigens that their native 3-dimentional structure is maintained in order to elicit protective 
immune responses. In such cases, the application of synthetic approaches is limited to 
sequences that can be readily refolded. Further, TLR-based adjuvants comprise various types 
of molecules (e.g. lipo-peptides/proteins/polysaccharides, nucleic acids and proteins),
18,21-26
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with different approaches required to produce each adjuvant. Finally, semisynthetic 
approaches combine the advantages of both synthetic and recombinant approaches, and hence 
can be used to produce conjugate vaccines composed of folded protein antigens and synthetic 
TLR agonists. In addition, limited ability of some TLR agonists to simulate potent immune 
responses due to the rapid dissolution may be resolved following their covalent attachment to 
antigens (e.g. conjugation of CpG oligodeoxynucleotide (ODN) onto HIV-1 Gag protein 
enhances the induction of adaptive immunity).
27,28
 
This review briefly summarizes different TLR agonists used as immunostimulatory adjuvants, 
along with their mechanisms of action, and provides an overview of different approaches used 
to develop antigen-TLR ligand conjugates. For each approach, different examples of TLR 
agonists that have been used in preclinical or clinical trials are provided. This review focuses 
on semisynthetic strategies, which include chemical ligation and enzyme-mediated ligation 
approaches. 
 
TOLL-LIKE RECEPTOR LIGANDS AS IMMUNOSTIMULATORY ADJUVANTS  
Adjuvants are designed to improve the immunogenicity of antigens in vaccines, by 
stimulating the immune system (i.e. immunopotentiators) or improving their delivery to 
antigen presenting cells (i.e. delivery systems).
8
 They are generally required to elicit 
protective immune responses against subunit and inactivated whole organism vaccines. Ideal 
adjuvants should possess properties such as the ability to prolong the duration of immune 
responses, as well as: stimulating rapid protective immune responses following an infection; 
stimulating both humoral and cell mediated immune responses; and reducing the cost of 
vaccination by reducing the required antigen dosage.
8
 The mechanism of action of adjuvants 
can be divided into two categories: 1) particulate vaccine delivery systems that deliver 
antigens to antigen presenting cells through which both humoral and cell mediated responses 
are enhanced, and 2) immunostimulatory adjuvants, which stimulate cells directly via specific 
receptors leading to quicker, more specific, and more potent immune responses.
1,8
 
 
Toll-Like Receptors. The innate immune system plays a fundamental role in protecting 
against bacterial, viral and parasite infections through the recognition of pathogen-associated 
molecular patterns (PAMPs) by PRRs.
29
 PAMPs are molecules produced by pathogens, that 
are not produced in the host, which activate the innate immune system to identify non-self 
molecules. There are several different types of PRRs that are associated with the early 
detection of pathogens following infection including TLRs, C-type lectin receptors (CLRs), 
RNA-sensing RIG-I (retinoic acid-inducible gene I)-like receptors (RLRs) and NOD-like 
receptors (NLRs). TLRs are transmembrane proteins, usually expressed by DCs, macrophages 
and B cells, which play a critical role in both the innate and adaptive immune responses. To 
date 13 TLRs have been classified, of which TLR1-10 have been identified in humans, and 
TLR1-9 and 11-13 have been identified in rodents. TLRs and interleukin-1 receptors (IL-1Rs) 
belong to the same superfamily, TLR/interleukin-1 receptors (TIRs), and share the same 
intracellular homology domain.
30
 The extracellular domains of TLRs are involved in the 
recognition of PAMPs. 
TLR1, 2, 5 and 6 are located on the surface of cells, with signaling through these receptors 
inducing TH2-type immune responses. In comparison, TLR3, 7, 8 and 9 are located on the 
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membrane of endosomal compartment and signaling via them induces TH1-type immune 
responses. TLR4 is expressed on both the cell surface and endosomal membranes. Surface 
expressed TLR4 signaling induces the production of proinflammatory cytokines, but can be 
switched to endosomal signaling under regulation of the p110δ isoform of 
phosphatidylinositol-3-OH kinase (PI(3)K), which results in the generation of 
anti-inflammatory cytokines.
31
 Finally, TLR10 is expressed on the cell surface but its ligand/s 
and functions are currently unknown.
32
 Based on their location, surface expressed TLRs are 
responsible for the detection of extracellular bacterial cell wall components
33-36
 while 
endosomal TLRs are associated with the recognition of intracellular nucleic acids from 
viruses and bacteria.
37-41
 
 
Toll-Like Receptor Signaling Pathways and Adjuvant Mechanisms. Following the 
binding of their ligands, TLRs undergo a conformational change by forming homo- and 
heterodimers which are necessary to trigger intracellular signaling. During this process, 
different adaptor proteins are recruited to the intracellular TIR domain, which are essential to 
drive the subsequent signaling. Four adaptor proteins have been identified including: myeloid 
differentiation primary response factor 88 (MyD88), TIR domain-containing adaptor protein 
(TIRAP, also known as Mal or MyD88 adaptor like protein), TIR domain-containing 
adapter-inducing interferon-β (TRIF, also known as TICAM-1) and TRIF-related adaptor 
molecule (TRAM, also known as TICAM-2).
42
 As shown in Figure 1, there are two signaling 
pathways responsible for the activation of intracellular cascades. These are the 
MyD88-dependent and MyD88-independent (also known as the TRIF-dependent) pathways.
43
 
All TLRs except TLR3 require MyD88 as the essential adaptor protein. TLR4 signaling can 
activate both MyD88-dependent and MyD88-independent pathways in association with the 
coreceptors CD14 and MD2, which are required for the recognition of its ligand 
lipopolysaccharide (LPS). In addition, the biological functions of TLR10 are not fully 
understood, although TLR10 has been reported to show inhibitory properties that control 
inflammatory responses mainly induced by TLR2.
32
  
The expression of TLRs by DCs, macrophages and B cells provides a means to uptake antigen 
when presented in the context of TLR ligands for presentation via major histocompatibility 
complex (MHC) I and II, thereby enhancing the production of antigen-specific antibodies and 
CTL responses. TLR signaling ultimately leads to the induction of pro- and anti-inflammatory 
mediators, which results in the development and proliferation of T cells, as well as promotion 
of memory T cells. The above features of TLRs make their ligands perfect candidates as 
immunostimulatory adjuvants in the context of vaccination. 
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Figure 1. TLR signaling pathways of common TLR ligands. TLRs can detect exogenous PAMPs, resulting in the 
activation of TLR signaling pathways that lead to the regulation of transcription factors and the release of 
proinflammatory cytokines and chemokines. In the MyD88-dependent pathway, MyD88 is recruited to the 
cytoplasmic TIR domain to activate interleukin-1 receptor-associated kinase (IRAK) 4 and IRAK1/2, followed 
by activation of tumor necrosis factor receptor-associated factor 6 (TRAF6).
43
 Ultimately, this pathway leads to 
nuclear translocation of transcription factors including activator protein 1 (AP1) and nuclear factor-κB (NF-κB) 
which mediate induction of pro-inflammatory cytokines and chemokines such as TNF, IL-6, 8, 12 and type I 
interferon (IFN). The MyD88-dependent pathway also results in the translocation of cAMP response 
element-binding protein (CREB) which mediates induction of TNF, IL-10 and cyclooxygenase-2 (COX-2). For 
MyD88-dependent signaling TLR1, 2, 4 and 6 require the cooperation of TIRAP while TLR 7, 8 and 9 do not.
42
 
TLR3 recruits TRIF to activate TRAF3 and thereafter interferon regulatory factor (IRF) 3 which results in the 
induction of IFN-β and IL-10. Unlike TLR3, TLR4 needs to firstly recruit TRAM before activating TRIF when 
signaling through the TRIF-dependent pathway. TLR7, TLR8 and TLR9 signaling leads to nuclear translocation 
of AP1 and NF-κB in MyD88-dependent pathway and activation of IRF7 and IRF1 that ultimately results in 
secretion of cytokines and chemokines such as TNF, IL-6, 12 and IFN-α, IFN-β. Overall TLR signaling results in 
host cell responses such as the induction of inflammatory mediators and production of antimicrobial agents. 
Many TLR agonists have been identified. For example, triacylated lipopeptide tripalmitoyl-S-glyceryl cysteine 
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(Pam3Cys) as a TLR1/TLR2 heterodimer agonist;
24,26
 diacylated lipopeptide dipalmitoyl-S-glyceryl cysteine 
(Pam2Cys), M. fermentans macrophage-activating lipopeptide (MALP-2) and fibroblast-stimulating lipopeptide 
(FSL)-1 as TLR2/TLR6 heterodimer agonists;24 dsRNA and Poly I:C as TLR3 agonists;23 MPLA as a TLR4 
agonist;
25
 bacterial heat shock protein complexes (HSPCs) including HSP70, HSP90 and gp96 possibly targeting 
TLR2 and TLR4;
44-46
 Bacterial flagellin as a TLR5 agonist;
18
 Imiquimod as a TLR7 agonist; ssRNA, 
gardiquimod, and resiquimod as TLR7/TLR8 heterodimer agonists; and CpG DNA and CpG ODNs as TLR9 
agonists.
21,22
 
 
Examples of Toll-Like Receptor Agonists as Immune Adjuvants. Several vaccines have 
been recently marketed, which feature TLR agonists as immunostimulatory adjuvants. An 
important recent example is Trumenba
®
, which includes two Neisseria meningitides factor H 
protein binding proteins that incorporate a covalently-linked, N-terminal bacterial lipopeptide 
TLR2 adjuvant similar to Pam3Cys.
47
 In comparison, the most recent adjuvant mixture 
approved by the US Food and Drug Administration (FDA) is AS04, an immunostimulatory 
adjuvant licensed in 2005 by GlaxoSmithKline (GSK).
48
 The major component of AS04 is 
MPLA, a derivative of the TLR4 agonist LPS. LPS consists of a hydrophobic lipid A 
component and a hydrophilic polysaccharide.
48
 TLR4, together with co-receptors CD14 and 
MD2, recognizes LPS through its lipid A component, activating inflammatory pathways.
49
 
This can lead to septic shock, and as such LPS cannot be used directly as an adjuvant in 
humans due to its high toxicity.
31
 Consequently, derivatives that do not possess this toxicity 
have been developed. MPLA is a detoxified analog which has a thousand times lower toxicity 
compared to LPS. AS04 consists of MPLA and aluminum hydroxide (AH) or aluminum 
phosphate (AP) depending on the vaccine design, and has been widely evaluated in many 
vaccines against viral diseases (e.g. hepatitis B virus (HBV), herpes simplex virus (HSV), 
human papillomavirus (HPV) and Epstein-Barr virus (EBV)). Fendrix (HBV) and Cervarix 
(HPV) are successful examples of commercial AS04-adjuvanted vaccines.
48
 Fendrix, 
developed by GSK and licensed by the FDA in 2005, has demonstrated its ability to induce 
longer lasting and higher titer antigen-specific antibodies compared to aluminum-adjuvanted 
vaccines, and elicits enhanced CTL responses in humans. Cervarix, containing HPV types 16 
and 18 antigens, has been approved for use in Australia and the USA in 2007 and 2009, 
respectively. This vaccine has been shown to induce a long-lasting immune response against 
both HPV-16 and -18 in females aged 9-25 years.
48
 Administration of both vaccines revealed 
that the high-levels of antibodies induced by AS04 also show strong virus neutralization 
capacity. The success of AS04 has paved the way for the utilization of other TLR agonists as 
marketable adjuvants. 
MPLA has also been intensively investigated as an adjuvant on its own. For example, Pollinex 
Quattro is an MPLA-adjuvanted vaccine that is used for seasonal allergic rhinitis therapy in 
Europe,
50
 and is progressing towards FDA approval. Further, MPLA has also been used in 
combination with Quillaja saponaria 21 (QS21) and liposomes to compose AS01, which is 
used in the first licensed malaria vaccine Mosquirix (GSK).
51
 Some other TLR agonists that 
are being investigated in vaccine clinical trials include: 1) Ampligen, a TLR3 agonist, which 
contains Poly I:C12U (a low toxicity Poly I:C analog) tested in phase I and II trials against 
ovarian, fallopian tube or primary peritoneal cancer, and tested in phase II and III trials 
targeting HIV;
23
 2) Flagellin, a TLR5 agonist that has been used in several influenza vaccines 
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including VAX102,
18
 VAX125,
17
 and VAX2012Q
19
 and tested in phase I and II trials; 3) 
Entolimod (CBLB502), an engineered flagellin analog tested in phase I studies targeting 
cancer;
52
 and 4) CpG7909 as a TLR9 agonist combined with QS21 and MPLA in a liposomal 
formulation named AS15 and tested in phase II trials against MAGE-A3-positive melanoma.
25
  
 
COVALENTLY ATTACHED TOLL-LIKE RECEPTOR LIGANDS IN 
ANTIGEN-ADJUVANT CONJUGATE VACCINES 
With the development of (bio)conjugation techniques, TLR ligands have been covalently 
attached to a number of molecules, from synthesized peptides to expressed proteins and even 
intact viruses.
53
 Normally antigens are delivered as a mixture with adjuvants. However, 
simple mixing cannot guarantee that delivered antigens will be recognized and presented by 
APCs, as the adjuvant and antigen may dissociate after administration. On the contrary, 
antigen-TLR ligand conjugates help to ensure that both antigen and adjuvant reach APCs 
simultaneously; are recognized by surface receptors on APCs; and are internalized together. 
Thus, more potent immune responses can be achieved by this approach when compared to 
those induced by antigen-TLR ligand mixtures. This in turn allows for the vaccine dose to be 
reduced, decreasing the likelihood of adverse effects. Since protein and peptide based 
antigens are produced by different approaches, various conjugation approaches have been 
developed to ensure the utility of these approaches for different antigen types. In this section, 
three covalent attachment strategies (e.g. recombinant fusion proteins; chemical conjugation; 
enzyme-mediated conjugation) that are most often utilized to produce protein and peptide 
antigen-TLR ligand conjugates will be discussed. 
 
Role of Toll-Like Receptor Ligands as Covalently Attached Immunostimulatory 
Adjuvants. TLR ligands, as immunostimulatory adjuvants, have multiple immunomodulatory 
functions including: modulation of APC migration and activation; up-regulation of 
costimulatory molecules on APCs for better antigen processing and presentation; induction of 
TH1, TH2 or TH17 responses through the polarization of CD4
+
 T cells; priming of CD8
+
 T 
cells for antigen-specific CTL responses; development of antibody responses and activation 
of natural killer (NK) cells (Figure 2).
43,44,47,54-58
 However, the co-administration of mixtures 
of TLR ligands and antigens may not elicit desired immune responses, due to several reasons: 
1) dissociation of the TLR ligands can occur rapidly after injection;
27
 2) it is more difficult to 
deliver free antigens to TLR receptor-expressing APCs for presentation than to deliver 
antigens linked to TLR ligands; and 3) antigen adjuvant mixtures tend to elicit lower potency 
immune responses compared to their fusions. In addition, many studies have confirmed that 
both innate and adaptive immune responses are generated with increased efficiency when 
antigens are covalently linked to TLR ligands.
27,59
 As shown in Figure 2, conjugated antigens 
are taken up by DCs more efficiently, thereby enhancing antigen presentation. Additionally, 
prolonged CTL responses are induced after antigen conjugates have been internalized by DCs 
through receptor-mediated endocytosis.
59
 This may be due to the formation of an intracellular 
antigen depot in DCs (Figure 2), containing the antigen conjugate, which leads to the 
continuous presentation of antigenic peptides (after antigen conjugates have been slowly 
released from the depot and processed) to T cells, thereby leading to long-term priming 
capacity.
59
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Figure 2. Putative mechanisms for the enhanced immunity associated with covalently attached TLR agonists. 
Administration of antigen-adjuvant fusions enables both antigen and TLR agonists to be delivered to the same 
DC at the same time, hence promoting efficient antigen presentation after conjugated antigens have been taken 
up by DCs. After internalization, TLR component helps to activate transcription factors that induce the 
production of cytokines and chemokines, such as IL-4 and IL-12, which help direct specific immune responses 
(e.g. TH1, TH2 and CTL type responses). Conjugated antigens are then processed in DCs, and their antigenic 
peptides are presented in the context of MHC class I or II molecules through presentation or cross presentation 
by DCs, which leads to the maturation of native CD4+ and CD8+ T cells.60-62 CD4+ T cells play a major role in 
shaping the adaptive immune system through: 1) promoting B cell maturation, which leads to the generation of 
memory B cells and long-lived plasma cells; 2) secreting different types of cytokines (e.g. IL-4, 5, 13 and IFN-γ), 
which play different roles in the development, maturation, and activation of macrophages and NK cells; and 3) 
activating CD8
+
 T cells and regulating CTL responses, which are central for host defenses against intracellular 
pathogens as well as the elimination of cancer cells.63-65 
 
Antigen-Toll-Like Receptor Ligand Conjugates Expressed as Recombinant Fusion 
Proteins. With the development of recombinant DNA technology, it is convenient to express 
antigen-TLR ligand conjugates in various hosts e.g. Escherichia coli (E. coli), yeast, insect 
and mammalian cells. As a well-established and cost-effective expression system, E.coli is the 
most popular system for the expression of heterologous proteins in a high yield. There are 
several advantages of using E.coli as an expression system: exogenous DNA can be 
transformed rapidly and easily; growth media are well defined and affordable; cells can grow 
to high density within a short period of time; and soluble expressed proteins carrying an 
affinity tag can be easily purified. On the other hand, some proteins may not express, express 
as insoluble aggregates (inclusion bodies), or express poorly (proteins with high molecular 
weight e.g. >75kDa) in this system. This may be due to protein toxicity, which interferes with 
normal E.coli growth, as well as codon bias which leads to depletion of low-abundance 
tRNAs. Also, if the proteins were expressed as inclusion bodies, it can be extremely difficult 
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to refold them back to their natural conformation. Furthermore, as a Gram-negative bacteria, 
E.coli produces endotoxins, which can elicit strong immune responses, sometimes leading to 
septic shock. Thus the chromatographic methods followed should be carefully selected to 
remove endotoxins during protein purification steps.  
Many TLR ligands have been investigated as fused recombinant proteins expressed by E.coli. 
The most successful example is Trumenba
®
, which is a self-adjuvanting (TLR2 agonist) 
lipoprotein vaccine against Meningococcal Meningitis group B.
47
 Bacterial flagellin (a TLR5 
ligand) has also been intensively studied in clinical trials as fusions with influenza 
antigens.
17-19
 Other examples tested in preclinical studies include Ag473, a TLR2 ligand fused 
to dengue virus envelope protein E3;
66
 HSP70 fused to HIV-1 p24 protein;
44
 and the type III 
repeat extra domain A from fibronectin (EDA) as TLR4 ligand fused to chicken ovalbumin 
(OVA) epitope.
45,53,66,67
 All the above examples will be discussed in the following paragraphs. 
Trumenba
®
 is the first vaccine approved by the FDA to protect against invasive disease 
caused by Neisseria meningitidis serogroup B (NMB) in individuals aged 10 to 25.
47
 
Trumenba
®
 is composed of two lipidated fHBP variants, A05 from subfamily A and B01 
from subfamily B, namely rLP2086-A05 and rLP2086-B01, respectively.
68
 fHBP, a key 
virulence factor also known as LP2086, is a conserved surface-exposed lipoprotein 
responsible for evasion from complement-mediated killing through binding to human 
complement factor H.
68,69
 rLP2086-A05 and rLP2086-B01 are both recombinantly expressed 
in E.coli, with an N-terminal lipid tail as per the native lipoproteins (Figure 3A).
47
 As a TLR2 
agonist, the lipid moiety is able to elicit broader immune responses against the antigens when 
compared to their non-lipidated forms.
47
 Clinical trials revealed that Trumenba
®
 was well 
tolerated and able to stimulate immune responses against a broad variety of group B 
meningococcal strains prevalent in the USA.
68
 Trumenba
®
 represents the first vaccine 
consisting of a covalently attached TLR ligand and a protein antigen. 
 
Figure 3. Schematic structure of bacterial lipo-peptides/proteins (TLR1/TLR2 or TLR2/TLR6 agonists). (A) 
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Trumenba
®
, (B) Ag473, (C) Pam2Cys and (D) Pam3Cys. 
 
Antigen-adjuvant fusion vaccines incorporating Salmonella typhimurium flagellin type 2 
(STF2) have also been tested in multiple clinical studies. Flagellin, a natural ligand of TLR5, 
is the major component of flagella in bacteria, and features four globular domains (0, 1, 2, and 
3) where domain 1 is recognized by TLR5 (Figure 4A).
70
 Flagellin fusion vaccine 
development strategies have included: 1) antigen of interest attached to the N- or C-terminus; 
2) antigen of interest replaces the D3 domain; 3) antigen of interest inserts into the D3 domain; 
and 4) a combination of any of the above.
17-19
 A phase I study using VAX102, a recombinant 
fusion protein consisting of four repeats of matrix protein 2 (M2e) linked to flagellin (Figure 
4B), has been completed and the results showed that VAX102 was well tolerated at doses up 
to 1 µg, with a four-fold increase in serum IgG anti-M2e antibody titers observed when 
compared to subjects who received placebo.
18
 In addition, a phase II trial targeting adults aged 
65 years and older has been completed for VAX125, a recombinant fusion protein composed 
of flagellin and a hemagglutinin globular head of the HA1 domain from strain A/Solomon 
Islands/3/2006 (Figure 4C). The results revealed that VAX125 is safe for in this group at 
doses up to 8 µg. Furthermore, a 10-fold increase in serum hemagglutination-inhibition (HAI) 
antibody geometric mean titer (GMT) was generated by VAX125 which is much better than 
2-fold increase, observed with the standard Fluzone vaccination.
17
 Finally, a phase II study of 
VAX2012Q, a quadrivalent influenza vaccine containing four different types of hemagglutinin 
globular head subunits (strain A/California/07/2009, A/Perth/16/2009, B/Wisconsin/01/2010, 
and B/Bangladesh/5945/2009) each of which is inserted within the D3 domain, or in place of 
the D3 domain, or in place of D3 and at the C-terminus, has recently been completed in adults 
aged 18-64 years. The results of this study demonstrated no serious safety issues at all dose 
levels and seroprotective immune responses were elicited.
19
 
 
Figure 4. Schematic representation of flagellin and flagellin fusion vaccine candidates. (A) Flagellin. (B) 
VAX102, flagellin (cyan) with the C-terminus fused with four tandem copies of the ectodomain of the M2e 
(green). (C) VAX125, flagellin (cyan) with the C-terminus fused with a globular head of the HA1 domain 
(orange). 
 
Lipidated meningococcal antigen Ag473 is a bacterial lipoprotein encoded by the NMB1468 
gene.
71
 The structure of recombinantly expressed Ag473 in E. coli has been characterized, as 
shown in Figure 3B.
72
 As a TLR2 agonist, Ag473 has the ability to activate DCs and promote 
their maturation. Furthermore, genetic fusions of the N-terminus of Ag473 to other antigens 
provide a method to recombinantly produce vaccines incorporating an N-terminal bacterial 
lipoprotein adjuvant. Immunization of mice with rlipo-D1E3 (envelope protein domain 3 from 
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dengue virus fused with the N-terminal 40-amino acids of Ag473) expressed in C43 (DE3) E. 
coli (which is necessary to produce the lipidated N-terminus) elicited higher titers of anti-E3 
IgG antibodies than observed with E3 alone or alum adjuvanted E3.
66
 The results also showed 
that rlipo-D1E3 elicited significantly more neutralizing antibodies against dengue virus-2 
compared to E3 adsorbed on aluminum phosphate.
66
  
The ability of HSPs to act as danger signals and induce TH1 and TH17-type responses makes 
them potential adjuvants for fusing with protein or peptide antigens.
73,74
 r4M2e.HSP70c was 
constructed and expressed in E.coli by linking four tandem repeats of influenza A virus M2e 
with a Mycobacterium tuberculosis C-terminal truncated HSP70.
75
 Compared with r4M2e, 
rHSP70c, or r4M2e adjuvanted with alum, r4M2e.HSP70c induced stronger and longer 
lasting humoral and cellular immune responses characterized by the enhanced production of 
M2e-specific IgG2a antibodies and the TH1 cytokine IFN-γ.
75
 Another study using murine 
HSP70 fused with HIV-1 p24 protein was conducted in BALB/c mice. The results 
demonstrated that HSP70 enhanced p24 protein engulfment by DCs and stimulated the 
activation of DCs. P24-specific IgG2b antibodies and IFN-γ were induced at a much higher 
levels compared to those induced by p24 alone.
45
  
Fibronectins are a group of extracellular matrix glycoproteins which participate in many 
pathological and physiological processes, especially those associated with fundamental cell 
processes such as cell growth, cell adhesion, cell migration and wound healing.
76,77
 EDA, 
encoded by an alternatively spliced type III exon, has been identified to exhibit the ability to 
stimulate TLR4 activity,
78
 which suggest that EDA could potentially be used as a vaccine 
adjuvant.
67
 Intravenous administration of an EDA fusion with an OVA CD8
+
 T cell epitope 
peptide to C57BL/6 mice demonstrated that OVA-specific CTL responses were induced by 
the fusion protein, but not by OVA CD8
+
 T cell epitope alone. In addition, proinflammatory 
cytokines (e.g. IL-12 and TNF-α) were secreted by by bone marrow (BM)-derived DCs 
following stimulation with the recombinant EDA proteins. These immune responses were 
sufficient to protect mice from challenge by OVA tumor cells. Further, EDA has been 
demonstrated to adjuvant high molecular weight proteins through the attachment of full length 
OVA to the C-terminus of EDA. This construct demonstrated similar enhancement of 
immunogenicity towards the attached OVA protein compared to the peptide antigen, 
demonstrating that EDA has the potential to be utilized as an adjuvant for the development of 
antigen-adjuvant fusion protein vaccines.
67
 
  
Semisynthetic Approaches to Attach Immunostimulants onto Antigens. Some TLR 
ligands cannot be expressed as recombinant proteins, hence they are chemically synthesized 
and attached to peptide or protein antigens. There are two commonly used covalent 
attachment approaches, chemical ligation and enzyme-mediated ligation. For classical 
chemical ligation approaches to be used successfully, the reactive site (e.g. a cysteine residue) 
must be readily accessible (i.e. not buried within the proteins 3D structure) to enable the 
conjugation reaction to proceed efficiently. Therefore, on occasion ligation reactions must be 
performed under denaturing conditions (e.g. using chaotropes such as 6 M guanidine or 8 M 
urea) in order to expose the reaction site. This limits their use for many protein antigens, for 
which correct folding is often a requirement to ensure the generation of appropriate immune 
responses. In addition, the rate and extent of the reaction between each component can be 
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greatly affected by the concentration of each component that can be achieved under the 
reaction conditions. Thus, denaturing conditions may be used to help prevent the aggregation 
and precipitation of each reactant at high concentrations, in order to allow for high yielding 
conjugation reactions. Further, in some cases, the use of lower concentrations of chaotropes 
(e.g. 2 M urea) may allow for a balance to be achieved between maintaining the solubility of 
each component and minimizing protein unfolding. While these conditions can benefit the 
rate and extent of chemical ligation approaches, enzyme-mediated ligations generally need to 
be conducted under native conditions in order to maintain the activity of the enzymes used to 
achieve the conjugation reaction. 
  
Chemical Ligation. Conventional chemical ligation techniques involve the use of thiol- or 
amine-reactive reagents, maleimides or N-hydroxysuccinimidyl (NHS) esters respectively, to 
form conjugates through the side-chain of cysteine or lysine residues (Figure 5A and 5C). 
Tyrosine, aspartic acid, glutamic acid residues and the N- or C-terminus of polypeptides have 
also been utilized as modification sites.
79
 Although the classic ligation methods are still in 
widespread use, a variety of approaches that enable site-specific attachment reactions onto 
proteins have been developed e.g. expressed protein ligation (EPL) which combines native 
chemical ligation (NCL)
80
 and intein to conjugate a synthetic peptide onto a expressed protein 
(Figure 5B).
81,82
 The NCL reaction generates a native peptide bond at the ligation site through 
a reaction that involves the attack of a thioester containing component by another component 
containing an N-terminal cysteine residue.
80
 This leaves a cysteine residue at the ligation site, 
which can be converted to an alanine by a desulfurization reaction to prevent the formation of 
disulfide bonds (Figure 5B).
24,80
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Figure 5. Examples of chemical ligation reactions suitable for the generation of antigen-adjuvant fusions. 
(A) Maleimide (thioether) ligation. (B) Expressed protein ligation. (C) Sulfo-SMCC (contains both NHS 
ester and maleimide group) was used in ligation reactions to conjugate the molecule of interest (contains a 
thiol group) onto antigen protein through lysine side-chains. 
 
The first application using a semisynthetic-ligation approach to conjugate a TLR agonist to an 
antigen involved the conjugation of OVA and a CpG ODN.
83-85
 The synthetic ODN 
(containing a 5' thiol group) was covalently attached to the OVA protein by modifying 
multiple OVA amino groups with sulfosuccinimidyl-4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (sulfo-SMCC) to form maleimides, followed by reaction with the 
CpG ODN (Figure 5C). In accordance with the immunological properties of TLR9 agonists, a 
TH1-biased immune response was induced in mice following immunization with this vaccine. 
Further, high-level antigen-specific CTL responses, which conferred protection against a 
lethal OVA tumor challenge, were demonstrated. This synthetic ODN was further conjugated 
to two other antigens including E. coli β-galactosidase and HIV-1 envelope glycoprotein 
gp120, the results revealed that TH1 cells were induced more rapidly, along with stronger 
CTL responses and greater titers of IgG2a antibodies compared to where antigen-ODN 
mixtures were administrated in BALB/c mice.
13
 Similar techniques have also been used to 
conjugate OVA to TLR7/8 agonists (i.e. 3M012 and 3M044; 3M pharmaceuticals).
15,16
 These 
OVA-TLR7/8 agonist conjugate vaccines were able to induce the migration of DCs to the 
lymph node, enhance presentation and cross-priming efficiency, and induce the secretion of 
type I IFN. 3M-012 has also been conjugated to HIV-1 gag protein and subcutaneous 
administration of this conjugate in C57BL/6 mice revealed that enhanced gag-specific CD8
+
 
T cell responses were induced, along with increased numbers of cells expressing CD127, a 
marker correlated with the differentiation of effector cells to memory cells.
28
 Isothiocyanate 
and maleimide derivatives of another TLR7 imidazoquinoline agonist have been covalently 
attached to model protein antigens such as α-lactalbumin and human serum albumin to 
evaluate the immunostimulatory profiles of this TLR7-agonistic imidazoquinoline.
86
 
Intramuscular administration of the α-lactalbumin conjugate and antigen adjuvant mixture in 
outbred CF-1 mice demonstrated that higher titer antigen specific IgM, IgG1, and IgG2a 
antibodies were elicited by the conjugate when compared to the mixture and more importantly, 
IgG antibodies induced by the conjugate were observed to have a higher affinity towards 
α-lactalbumin.
86
 
The TLR3 ligand Poly I:C has been used in a Mycobacterium tuberculosis antigen-adjuvant 
fusion vaccine consisting of Ag85B-HspX (AH) fusion protein and Arabinogalactan (AG).
12
 
Ag85B, the major protein secreted by actively replicating M. tuberculosis, plays an essential 
role in the virulence of M. tuberculosis;
87
 is highly immunogenic, and induces a TH1-type 
immune response.
88
 HspX, a latency-associated antigen and molecular chaperone, is the 
dominant protein produced by M. tuberculosis in latently infected TB patients, and has been 
reported to be critical in the growth of M. tuberculosis following infection.
89,90
 AG, approved 
by the FDA as a food supplement, is a natural polysaccharide that can effectively activate 
immune responses through prompting splenocytes proliferation, upregulating the expression 
of various cytokines, and stimulating anti-tumour immunity.
91
 Poly I:C was activated by 
incubation with ethylenediamine and sodium bisulfate. Periodate oxidized AG was incubated 
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with activated Poly I:C and sodium cyanoborohydride to generate a potent adjuvant AG-P. 
Recombinant protein AH was then conjugated to AG-P in the presence of excess 
1-(3-(dimethylamino)propyl)-3-ethylcarbodimide through the C-terminal carboxyl groups. 
Intraperitoneal immunization with this compound in C57BL/6 mice revealed that AH-specific 
IgG antibodies and mixed TH1/TH2-type cytokines were elicited at significantly greater levels 
by AH-AG-P than induced by AH, AH-AG, AH-P, or a mixture of AH/AG-P. The higher 
efficiency observed with this antigen-adjuvant delivery system was due to two reasons. Firstly, 
AH is protected from proteolytic digestion through conjugation with AG-P, thereby 
prolonging the exposure time in vivo. Secondly, this approach ensures the simultaneous 
uptake of both AH and AG-P by DC, thereby increasing the presentation efficiency 
significantly. 
Bacterial lipopeptides and their synthetic agonists have also been shown to be ideal 
candidates for antigen-TLR ligand conjugate vaccines. TLR2/6 and TLR1/2 heterodimer 
ligands Pam2Cys (Figure 3C) and Pam3Cys (Figure 3D) are typical examples which have 
been chemically attached to antigens.
24,92
 For example, we observed that administration of a 
Pam2Cys, Pam3Cys or bacterial lipopeptide analog (lipid core peptide (LCP)) that was 
conjugated using EPL or maleimide chemistry onto a multiantigenic model group A 
streptococcus (GAS) antigen, containing a broadly protective (J14) and 7 strain-specific 
(N-terminal M protein peptides) peptide antigens, significantly enhanced production of 
antigen specific IgG antibodies.
24
 The Mxe GyrA Intein, fused to the same GAS antigen on 
the C-terminus, can be converted to a reactive α-thioester in several steps. Following that, 
lipid adjuvant peptides were conjugated to the recombinant thioester antigen through NCL in 
the presence of 6M guanidine. In this case utilization of denaturant will not cause issues since 
the GAS polytope antigen is mainly composed by linear peptide antigens without structure. 
Results showed that persistent antigen specific IgG antibodies were rapidly elicited after 
immunization. The major issue when performing conjugation in this case is the high 
hydrophobicity of the lipopeptides, which led to insoluble precipitates in aqueous solvents 
during preparation. It is very common to utilize denaturant such as organic solvent and 
chaotropic agent to improve the solubility of lipid adjuvants, which unfortunately will most 
probably result in disruption of native structure of the administrated antigens. 
 
Enzyme-Mediated Ligation. Enzyme-mediated ligation reactions have attracted significant 
attention in recent years due to their many advantages, which include the ability to simply and 
efficiently, site-specifically modify proteins, under conditions that maintain their native 
structure. This is highly significant, as the majority of the antigens reported in the literature 
are folded protein antigens. A number of enzymes have been successfully used for 
bioconjugation reactions with proteins. These include: Staphylococcus aureus sortase A 
(SrtAsa)
93
 and Streptococcus pyogenes sortase A (SpSrtA);
94,95
 Clitoria ternatea butelase 
1;
96,97
 Oldenlandia affinis (O. affinis) asparaginyl endopeptidase (OaAEP);
98-100
 
SpyLigase;
101,102
 transglutaminase (TGase);
103,104
 phosphopantetheinyl transferases 
(PPTases);
105
 biotin ligase;
106
 and lipoic acid ligase.
107
 In the following paragraphs, a brief 
description of some of the leading enzyme-mediated ligation approaches (OaAEP, butelase 1 
and sortase A) will be provided. 
The asparaginyl endopeptidase, OaAEP1b,
98
 represents one of the most recently identified 
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enzymes used for enzyme-mediated ligations. It was identified from O. affinis, a plant that 
produces cyclotides (small cyclic peptides, characterized by a cyclic cystine knot motif). 
During cyclotide maturation, the N- and C-terminal propeptides of the linear cyclotide 
precursor are cleaved, followed by ligation of the N- and C-terminus by a cyclase. AEP1b is a 
cyclase responsible for cyclotide generation in O. affinis. It is readily overexpressed in E. coli, 
and also possesses the capacity to cyclize unrelated peptides/proteins (Figure 6A),
98
 thus 
allowing for its use as a ligase enzyme for protein and peptide ligation reactions.
100
 The 
ligation reaction also benefits from the requirement for the presence of relatively short 
flanking sequences on each peptide/protein component, with highly efficient ligations 
observed where one species possesses a C-terminal Asn-Gly-Leu motif, and the other two 
N-terminal flanking residues Gly/Lys/Gln-Leu (Figure 6B).
98,100
 However, despite these 
favorable characteristics, the purification of AEP1b is complicated; requires proteolytic 
activation at pH 4.5; and is low yielding (~ 1.8 mg/L). Further, ligation reactions are slow, 
taking up to 22 h to complete, which may impede its widespread application. A mutant 
OaAEP1 (Cys247Ala) has been identified recently, with significantly increased ligase activity 
around 160 times higher compared to WT OaAEP1, which will greatly extend its 
applications.
108
  
 
Figure 6. Schematic representation of OaAEP1b-mediated ligation. (A) Non-OaAEP peptides can be 
cyclized when fused to the recognition motifs present in the O. affinis cyclotide precursor. Peptide contains 
the C-terminal recognition sequence Cys-Thr-Arg-Asn-Gly-Leu-Pro-Ser and the N-terminal recognition 
sequence Gly-Leu-Pro-Val in this example. (B) For efficient ligation, C-terminal and N-terminal 
recognition sequences can be simplified to Asn-Gly-Leu and Gln/Lys/Gly-Leu, respectively. 
 
Another recent addition to the enzyme-mediated ligation toolkit is Butelase 1 from the 
tropical plant Clitoria ternatea.
97
 This enzyme, like AEP1b, is a cyclase. Further, it has been 
reported to be the fastest-acting ligase known to date, and has been used in various studies for 
the ligation or cyclization of peptides and proteins.
96,109,110
 The required flanking sequences 
are also simple, e.g. an Asp/Asn-His-Val motif at the C-terminus of peptide 1 and a 
Xaa-Ile/Leu/Val/Cys motif at the N-terminus of peptide 2 (Figure 7; where Xaa is any amino 
acid except proline). The catalytic efficiency for typical butelase-mediated reactions is very 
high, with only 5 min needed for peptide cyclisation compared to 22 hours with WT 
OaAEP1b. Thus, these advantages make butelase 1 an ideal enzyme for peptide and protein 
engineering. However, butelase 1 is currently unable to be expressed in E. coli, and thus 
needs to be extracted from Clitoria ternatea. As there is no built in affinity purification handle, 
a complex 3-day, 4-step chromatography procedure is required to obtain pure butelase 1.
96
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Figure 7. Schematic representation of Butelase-mediated ligation. 
 
Finally, sortase A has been extensively evaluated as a ligase and cyclase for biotechnology 
applications.
93,94,111
 Sortases are transpeptidase enzymes that are found in the cell envelope of 
almost all Gram-positive bacteria, where they are responsible for the covalent attachment of 
proteins to the cell wall peptidoglycan layer.
111
 Sortase A, also known as the housekeeping 
sortase, recognizes a Leu-Pro-Xaa-Thr-Gly sequence, which it cleaves between the Thr and 
Gly residues to form a thioester intermediate (Figure 8; where Xaa is any amino acid). The 
thioester is then attacked by an N-terminal glycine amine to generate a native peptide bond 
between the Thr carboxyl group and the Gly amino group.
111
 Kinetic analysis of sortase 
transpeptidation reactions revealed that N-terminal oligoglycine is required for efficient 
SrtAsa-mediated ligations.
112,113
 
As the first sortase to be described, SrtAsa is also the most thoroughly characterised and 
commonly used for ligation and cyclization reactions. Further, it can be efficiently expressed 
and purified in E. coli. However, the catalytic efficiency of SrtAsa is poor, possibly due to the 
Km LPXTG is relatively high, about 8.7mM.
114,115
 Thus, a directed evolution strategy has been 
used to improve its catalytic efficiency.
116
 After eight rounds of screening, a SrtAsa variant 
containing five mutations (P94R/D160N/D165A/K190E/K196T) was isolated, which 
demonstrated a 140-fold increase in catalytic activity. We have assessed this enzyme for the 
site-specific attachment of a synthetic bacterial lipopeptide agonist (TLR2/6 agonist), 
modified to incorporate an N-terminal tri-glycine, onto a recombinant protein antigen, 
incorporating a C-terminal LPETG sequence (unpublished data, Z Xu and P Moyle). Use of 
this enzyme provided access to ligation reactions that proceeded to approximately 90 % 
completion, over the course of a couple of hours, with approximately 100-fold less sortase 
enzyme required when compared to the wild-type sequence. This reaction represents the first 
time that a bacterial lipopeptide TLR2 ligand has been fused to a protein antigen under native 
conditions, and thus this technique has significant potential to be used for the development of 
vaccines against a variety of different pathogens. 
 
Figure 8. Schematic representation of SrtAsa-mediated ligation. 
 
Synthetic Approaches. As the standard method for synthesizing peptides and small proteins, 
solid-phase peptide synthesis (SPPS) has been widely used when the desired product is 
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difficult to express or where unnatural amino acids or other unnatural modifications are 
desired. Selected B cell, CD4
+
 or CD8
+
 T cell epitopes can be economically produced by 
SPPS in a chemically-defined manner. These synthetic short peptides have the capacity to 
generate protective immunity following immunization. Vaccines that incorporate one or more 
synthetic peptide epitopes represent a highly-defined approach to immunization. The covalent 
attachment of TLR ligands onto these synthetic peptides represents a promising approach to 
stimulate the innate immune system to induce potent T- and B-cell responses. The selected 
TLR ligands should be well-defined and their synthesis, or chemical modification should be 
ammeniable to simple, large scale production. Some lipopeptide TLR2 agonists, such as 
Pam2Cys and Pam3Cys, contain an amino acid scaffold, and hence can be easily conjugated 
onto peptide antigens during SPPS.
14,117-120
 In addition, TLR7, 8 and 9 agonists have also 
been conjugated onto peptides to produce self-adjuvanting vaccines.
118,121-123
 
Fully synthetic vaccines composed of a model OVA CTL antigen (DEVSGLEQLESIINFEKL; 
OVA247-264) fused with the TLR2 ligand Pam3CysSK4 and TLR9 ligand CpG ODN 
(5'-TCCATGACGTTCCTGACGTT-3') have been designed and produced with high quality, 
and without contamination by other TLR ligands such as LPS.
14,118
 Uptake and trafficking of 
these conjugates by DCs demonstrated that although distinct receptors are involved in the 
uptake of different TLR ligand conjugates, each conjugate is taken up by DCs much more 
efficiently than unconjugated mixtures both in vitro and in vivo, indicating that the covalent 
conjugation is responsible for the enhanced uptake.
118
 OVA247-264 was also fused to 
Pam3CysSK4 derivatives by the same group. After immunizing naïve C57BL/6 mice, the 
OVA epitope specific CD8
+
 T cell responses were significantly higher in mice immunized 
with the TLR ligand-peptide conjugates compared to mixtures of the peptide and TLR ligand, 
indicating that conjugates were efficiently introduced into the MHC I cross-presentation 
pathway.
14
  
Normally TLR7/8 ligands are conjugated onto proteins or peptides through N-terminal or 
lysine side chain amino groups.
121,122
 In such cases, the homogeneity of final product may 
cause concern when multiple reaction sites are present in antigens. A novel TLR7/8 agonist, 
norleucine containing an imidazoquinoline moiety on its side chain, has been developed and 
this compound can be attached to different peptide antigens in a molecular-defined manner 
during SPPS.
123
 This molecule was covalently attached to influenza A virus M2e peptide and 
the conjugates were subcutaneously injected in mice. Results revealed that M2e-specific 
antibody responses were induced by the peptide conjugates, but not by M2e or equimolar 
M2e and TLR7/8 ligand mixtures.
123
 
Numerous studies have investigated the conjugation of TLR2 agonists onto different virus 
antigen epitopes.
119
 For example, a HSV glycoprotein B (gB) CTL epitope fused with the Pan 
DR epitope (PADRE, a universal CD4
+
 helper T cell epitope) has been synthesized and linked 
to three palmitic acid moieties to comprise a TH-CTL lipopeptide.
119
 Results from intravaginal 
administration of this lipopeptide in mice have shown that HSV-specific effector and memory 
CTL responses as well as TH1 biased cytokines were induced. Furthermore, immunization 
with lipopeptide conjugates instead of peptides alone conferred protection in mice against 
genital HSV-2 challenge. TLR2 ligand-synthetic peptide conjugates have also been tested in 
clinical studies.
120,124
 Two HPV16 synthetic long peptides (SLPs), harboring multiple CD4
+
 
and CD8
+
 T cell epitopes that cover two most immunogenic regions of E6 oncogenic protein 
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respectively, have been covalently attached to Amplivant (AV) under GMP environment.
120
 
Amplivant is a TLR2 agonist Pam3CSK4 based ligand with modification on one of the lipid 
tails to enhance its binding capacity to TLR2. Both AV-SLP conjugates have the capacity to 
stimulate the maturation of human DCs in vitro. Enhanced secretion of chemokines such as 
IL-8, IL-10, MCP-1, CCL3, and CCL4 was observed in vivo when administrated with 
AV-SLPs in comparison to SLP alone. HPV16-specific CD8
+
 and CD4
+
 immune responses 
were induced and AV-SLPs were presented to DCs more efficiently than the free SLPs. 
Moreover, TH1 biased cytokines were induced effectively by AV-SLPs in patient-derived 
lymph node T cells. A phase I/II clinical trial is currently being conducted in HPV16 positive 
cancer patients to assess the safety and immunogenicity of AV-SLPs.
120
 An additional 
example is a HIV vaccine comprised of large synthetic fragments from viral proteins 
featuring a covalently attached palmitoyl chain. This vaccine has achieved its goal in phase 
I/II trials, which evaluated its systemic safety as well as its capacity to elicit antigen specific 
CTL responses.
124
 
 
Safety of Antigen Immunostimulant Conjugates. TLR agonists selected for covalent 
attachment are normally highly potent immunostimulants, inducing the secretion of high 
levels of proinflammatory cytokines and vasoactive substances, which may cause strong local 
inflammatory responses and contribute to the formation of systemic cytokine storm-like 
effects following administration.
125
 Systemic dissemination of both antigens and TLR 
agonists is also observed to induce non-specific immune activation, which might lead to 
toxicity (e.g. proinflammatory cytokines) or undesired side effects (e.g. autoimmunity). Thus, 
when employed as adjuvants, TLR agonists may be associated with safety and tolerability 
concerns. Different strategies have been developed to tackle these issues, including: molecular 
modifications to produce TLR agonist derivatives that minimize systemic dissemination from 
their site of administration,
126
 or improve their toxicity profile;
23,48
 the development of 
candidates with limited biodistribution to minimize their off-site inflammatory impact (e.g. 
avoiding ‘wasted inflammation’);
127
 optimizing formulations by incorporating TLR agonists 
into particulate carriers to control their release kinetics;
128
 and conjugation of TLR agonists 
onto antigens.
129
 Conjugating TLR agonists onto antigens enables efficient and precise 
delivery of both components to the same APC, which in turn reduces the required antigen and 
TLR agonist doses, thereby resulting in a decreased frequency of adverse effects. Thus, 
covalently attaching antigens with TLR agonists offers the possibility to dramatically reduce 
systemic exposure of these immunostimulants, but with sufficient vaccine components 
maintained at the local site during administration. Based on the results from clinical studies, 
concerns regarding the safety of antigen immunostimulant conjugate vaccines are unlikely to 
be of concern where doses have been evaluated, controlled and optimized. For example, 
influenza vaccines VAX 102/125/2012Q, all containing the TLR5 agonist Flagellin, cause no 
safety issues at the doses assessed in multiple phase I/II studies.
17-19
 Trumenba
®
,
 
which 
incorporates an N-terminal bacterial lipopeptide TLR2 agonist, was also well tolerated in 
human clinical trials.
68
 Many other antigen-adjuvant conjugate vaccine candidates have also 
been demonstrated to be effective in animal models. Optimization of these conjugates to limit 
adjuvant related side effects and toxicity will be of high importance to ensure they are safe 
and well tolerated for human use. 
Page 18 of 36
ACS Paragon Plus Environment
Bioconjugate Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19 
 
 
CONCLUSION 
Compared to traditional attenuated or inactivated vaccines, protein and peptide based vaccines 
are safer, easier to produce, and can elicit a more defined immune responses. However, 
protein or peptide antigens are normally poorly immunogenic, requiring adjuvants to improve 
their efficacy. Various adjuvants have proven to be effective at directing different types of 
adaptive immune responses. Among these adjuvants, TLR agonists are special since TLRs 
play a key role in regulating innate and adaptive immune responses to antigens. TLR agonists 
can activate DCs, facilitating the uptake of antigens and presentation of antigenic peptides in 
the context of MHC molecules. Adaptive immunity is then established through activation of 
antigen specific T lymphocytes and induction of specific humoral and cell mediated responses. 
Higher efficiency antigen presentation can be achieved where the antigen and TLR adjuvant 
are covalently attached together. Thus, developing subunit vaccine candidates with built-in 
TLR agonists has attracted wide attention in vaccine research and development. Different 
approaches, both chemical and biological, have been developed to produce protein or peptide 
based antigen-TLR ligand conjugates. However, the manufacturing of such conjugates is very 
sophisticated, and includes the chemical synthesis of peptide antigens or expression of protein 
antigens, the chemical synthesis or expression of TLR agonists, and their conjugation. Each 
step requires strict quality control to ensure that batch-to-bath quality is consistent and 
regulatory requirements are fully met. Most recently, the approval of Trumenba
®
, the first and 
the only commercial vaccine in this area, demonstrates the full potential of antigen-TLR 
ligand conjugate vaccines in extending the current vaccine pipeline and tackling unmet 
demands. This exciting achievement will potentially accelerate the development of various 
conjugation approaches with application to a number of different TLR agonists. Protein and 
peptide-based antigen-TLR ligand conjugate vaccines are on the cutting edge of vaccine 
research with intense ongoing research activities likely to lead to much more licensed 
products in the near future. 
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Figure 1. TLR signaling pathways of common TLR ligands. TLRs can detect exogenous PAMPs, resulting in 
the activation of TLR signaling pathways that lead to the regulation of transcription factors and the release 
of proinflammatory cytokines and chemokines. In the MyD88-dependent pathway, MyD88 is recruited to the 
cytoplasmic TIR domain to activate interleukin-1 receptor-associated kinase (IRAK) 4 and IRAK1/2, followed 
by activation of tumor necrosis factor receptor-associated factor 6 (TRAF6).43 Ultimately, this pathway leads 
to nuclear translocation of transcription factors including activator protein 1 (AP1) and nuclear factor-κB 
(NF-κB) which mediate induction of pro-inflammatory cytokines and chemokines such as TNF, IL-6, 8, 12 
and type I interferon (IFN). The MyD88-dependent pathway also results in the translocation of cAMP 
response element-binding protein (CREB) which mediates induction of TNF, IL-10 and cyclooxygenase-2 
(COX-2). For MyD88-dependent signaling TLR1, 2, 4 and 6 require the cooperation of TIRAP while TLR 7, 8 
and 9 do not.42 TLR3 recruits TRIF to activate TRAF3 and thereafter interferon regulatory factor (IRF) 3 
which results in the induction of IFN-β and IL-10. Unlike TLR3, TLR4 needs to firstly recruit TRAM before 
activating TRIF when signaling through the TRIF-dependent pathway. TLR7, TLR8 and TLR9 signaling leads 
to nuclear translocation of AP1 and NF-κB in MyD88-dependent pathway and activation of IRF7 and IRF1 
that ultimately results in secretion of cytokines and chemokines such as TNF, IL-6, 12 and IFN-α, IFN-β. 
Overall TLR signaling results in host cell responses such as the induction of inflammatory mediators and 
production of antimicrobial agents. Many TLR agonists have been identified. For example, triacylated 
lipopeptide tripalmitoyl-S-glyceryl cysteine (Pam3Cys) as a TLR1/TLR2 heterodimer agonist;24,26 diacylated 
lipopeptide dipalmitoyl-S-glyceryl cysteine (Pam2Cys), M. fermentans macrophage-activating lipopeptide 
(MALP-2) and fibroblast-stimulating lipopeptide (FSL)-1 as TLR2/TLR6 heterodimer agonists;24 dsRNA and 
Poly I:C as TLR3 agonists;23 MPLA as a TLR4 agonist;25 bacterial heat shock protein complexes (HSPCs) 
including HSP70, HSP90 and gp96 possibly targeting TLR2 and TLR4;44-46 Bacterial flagellin as a TLR5 
agonist;18 Imiquimod as a TLR7 agonist; ssRNA, gardiquimod, and resiquimod as TLR7/TLR8 heterodimer 
agonists; and CpG DNA and CpG ODNs as TLR9 agonists.21,22  
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Figure 2. Putative mechanisms for the enhanced immunity associated with covalently attached TLR agonists. 
Administration of antigen-adjuvant fusions enables both antigen and TLR agonists to be delivered to the 
same DC at the same time, hence promoting efficient antigen presentation after conjugated antigens have 
been taken up by DCs. After internalization, TLR component helps to activate transcription factors that 
induce the production of cytokines and chemokines, such as IL-4 and IL-12, which help direct specific 
immune responses (e.g. TH1, TH2 and CTL type responses). Conjugated antigens are then processed in 
DCs, and their antigenic peptides are presented in the context of MHC class I or II molecules through 
presentation or cross presentation by DCs, which leads to the maturation of native CD4+ and CD8+ T 
cells.60-62 CD4+ T cells play a major role in shaping the adaptive immune system through: 1) promoting B 
cell maturation, which leads to the generation of memory B cells and long-lived plasma cells; 2) secreting 
different types of cytokines (e.g. IL-4, 5, 13 and IFN-γ), which play different roles in the development, 
maturation, and activation of macrophages and NK cells; and 3) activating CD8+ T cells and regulating CTL 
responses, which are central for host defenses against intracellular pathogens as well as the elimination of 
cancer cells.63-65  
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Figure 4. Schematic representation of flagellin and flagellin fusion vaccine candidates. (A) Flagellin. (B) 
VAX102, flagellin (cyan) with the C-terminus fused with four tandem copies of the ectodomain of the M2e 
(green). (C) VAX125, flagellin (cyan) with the C-terminus fused with a globular head of the HA1 domain 
(orange).  
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Figure 5. Examples of chemical ligation reactions suitable for the generation of antigen-adjuvant fusions. (A) 
Maleimide (thioether) ligation. (B) Expressed protein ligation. (C) Sulfo-SMCC (contains both NHS ester and 
maleimide group) was used in ligation reactions to conjugate the molecule of interest (contains a thiol 
group) onto antigen protein through lysine side-chains.  
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Figure 6. Schematic representation of OaAEP1b-mediated ligation. (A) Non-OaAEP peptides can be cyclized 
when fused to the recognition motifs present in the O. affinis cyclotide precursor. Peptide contains the C-
terminal recognition sequence Cys-Thr-Arg-Asn-Gly-Leu-Pro-Ser and the N-terminal recognition sequence 
Gly-Leu-Pro-Val in this example. (B) For efficient ligation, C-terminal and N-terminal recognition sequences 
can be simplified to Asn-Gly-Leu and Gln/Lys/Gly-Leu, respectively.  
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Figure 7. Schematic representation of Butelase-mediated ligation.  
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Figure 8. Schematic representation of SrtAsa-mediated ligation.  
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